Insider Selling: Fennec Pharmaceuticals Inc. (TSE:FRX) Senior Officer Sells C$207,029.47 in Stock

Fennec Pharmaceuticals Inc. (TSE:FRX) Senior Officer Adrian J. Haigh sold 22,223 shares of the firm’s stock in a transaction dated Tuesday, April 23rd. The stock was sold at an average price of C$9.32, for a total value of C$207,029.47.

Adrian J. Haigh also recently made the following trade(s):

• On Monday, April 15th, Adrian J. Haigh bought 22,222 shares of Fennec Pharmaceuticals stock. The shares were acquired at an average cost of C$2.31 per share, for a total transaction of C$51,332.82.

Fennec Pharmaceuticals Stock Performance

FRX opened at C$12.80 on Friday. The firm has a market cap of C$346.11 million, a price-to-earnings ratio of -12.55 and a beta of 0.35. Fennec Pharmaceuticals Inc. has a 52 week low of C$9.27 and a 52 week high of C$15.43. The business’s 50 day moving average is C$13.51 and its two-hundred day moving average is C$12.74. The company has a quick ratio of 10.17, a current ratio of 3.29 and a debt-to-equity ratio of 881.09.

Fennec Pharmaceuticals (TSE:FRX) last released its quarterly earnings results on Thursday, March 21st. The biopharmaceutical company reported C($0.14) EPS for the quarter, missing the consensus estimate of C$0.02 by C($0.16). Fennec Pharmaceuticals had a negative return on equity of 1,005.59% and a negative net margin of 75.50%. The firm had revenue of C$13.25 million for the quarter, compared to analyst estimates of C$12.88 million. On average, research analysts predict that Fennec Pharmaceuticals Inc. will post 0.4202312 EPS for the current year.

About Fennec Pharmaceuticals

Fennec Pharmaceuticals Inc operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons.